SG Americas Securities LLC Makes New Investment in Humacyte, Inc. (NASDAQ:HUMA)

SG Americas Securities LLC bought a new stake in shares of Humacyte, Inc. (NASDAQ:HUMA) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 32,074 shares of the company’s stock, valued at approximately $174,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. nVerses Capital LLC purchased a new position in shares of Humacyte in the 2nd quarter worth about $28,000. Hartline Investment Corp bought a new position in Humacyte in the 1st quarter valued at approximately $70,000. Principal Financial Group Inc. bought a new position in Humacyte in the 2nd quarter valued at approximately $83,000. Profund Advisors LLC purchased a new stake in Humacyte during the 2nd quarter valued at $97,000. Finally, XTX Topco Ltd bought a new stake in shares of Humacyte in the 2nd quarter worth $110,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Stock Up 4.4 %

HUMA stock opened at $5.72 on Thursday. The business’s 50-day moving average price is $5.72 and its 200-day moving average price is $5.96. The stock has a market cap of $681.16 million, a P/E ratio of -5.72 and a beta of 1.45. Humacyte, Inc. has a twelve month low of $1.96 and a twelve month high of $9.97. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, equities research analysts forecast that Humacyte, Inc. will post -1.09 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the company. EF Hutton Acquisition Co. I raised Humacyte to a “strong-buy” rating in a report on Monday, September 9th. TD Cowen restated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a report on Friday, September 20th. BTIG Research reiterated a “buy” rating and set a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Finally, Piper Sandler set a $6.00 price target on Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $10.00.

Insiders Place Their Bets

In related news, Director Brady W. Dougan sold 352,112 shares of the business’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the transaction, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Humacyte news, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total value of $2,235,911.20. Following the sale, the director now directly owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Kathleen Sebelius sold 5,182 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total transaction of $27,982.80. Following the completion of the sale, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,084,153 shares of company stock worth $6,869,996. Corporate insiders own 23.10% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.